NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









C2N Diagnostics

C2N Diagnostics

Private
Saint Louis, MichiganHealthcare & Life Scienceshttps://c2n.com/

Last Round

Strategic

Mar 13, 2025

Total Funding Raised

$75.47M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

C2N Diagnostics is a biotechnology company that provides innovative diagnostics and therapies for Alzheimer's disease through advanced mass spectrometry techniques for the identification and monitoring of biomolecules related to neurological disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

alzheimer's blood testbiomarker testingliquid biopsyamyloid testingclinical trial recruitmentmass spectrometryneurodegenerative diagnosticsbrain health diagnosticsclinical laboratory servicesCLIA-certified labdementia screeningamyloid plaque detectiontau biomarkersnon-invasive diagnostics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

C2N Diagnostics Comparables

Compare C2N Diagnostics with similar companies based on industry and business-model similarity.

C2N Diagnostics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
NeuroQuest
82%
Sunbird Bio
80%
Pre Diagnostics AS
80%

C2N Diagnostics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
StrategicMar 13, 2025
GrantJan 15, 2025
GrantSep 25, 2024
StrategicMar 6, 2024
Private EquityFeb 16, 2023
Grant
Sep 24, 2020

Key People

Founding team and executive leadership

Joel Braunstein

CEO, Co-Founder And Board Member

Founding Team

C2N Diagnostics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 11, 2026

    Alzheimer's diagnostic tests now available in South Korea via BeauBrain Healthcare partnership.

  • Mar 11, 2026

    Launched Precivity Portfolio blood tests for Alzheimer's diagnosis in South Korea.

C2N Diagnostics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

C2N Diagnostics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about C2N Diagnostics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSaint Louis, Michigan
Employee Range111
Year Founded2007
Last FundingMar 13, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.